By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.
The Real World Evidence revolution.
Our aim is to focus on cutting edge pragmatic Real-World Evidence (RWE) Studies to generate clinically meaningful data and physician experience faster, unlocking the true potential of these transformational therapies sooner.
We believe it’s the best way to ensure rapid, safe and appropriate access to reimbursed psychedelic medicines.
*Timeline to develop and trial KRN-101 to address cancer-related anxiety & depression.
"These are not studies driven by drug development companies. These are studies driven by clinicians to help patients."
Driving positive change.
Psychedelic based medicines will change the way mental health is treated, and as a result, we believe the human experience as a whole will improve.
Leading academics are demonstrating success with psychedelic medicines as therapy for treatment-resistant depression, anxiety, drug addiction and much more.
The human brain on psychedelics
Placebo
Psilocybin
FDA Breakthrough Designation
FDA has granted three breakthrough therapy designations. One for MDMA and two psilocybin.
Legally Accepted Therapeutic Use
September 2020, Court approved legal access of Psilocybin therapy for cancer related anxiety – BC, Canada
Continued Sucess for Cancer Related Distress
80% of cancer patients showed major reductions in psychological distress, for up to seven months after only a single-dose administration.
Let us tell you more.
We will email you to start the conversation.
Portable, scalable strategy for revenue growth.
Albert Labs is a catalyst leading a collaboration with academic institutions, hospital networks and existing reimbursement mechanisms.
- Leveraging existing clinic & research infrastructure.
- Academic partnerships drive next gen psychedelic R&D.
- Preidenitfied, accessible patient pools.
- Proprietary Real World Data to gain early reimbursement.
- In-house lab results in formulation & delivery IP.
Alberts Labs’ mission to ensure accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs.
Real World Evidence for patient acquisition.
Science and continuity for patients in need. Beginning with cancer related distress & existential crisis, we plan to initiate our first Real World Evidence studies across the UK and Europe.
1) 1000 Patient Cohort
Develop safe natural psilocybin therapeutics for cancer related anxiety & depression.
2) Expand Patient Cohort
Increase to multi-centre cancer hospitals with an international scope. Data collection and publishing.
3) Broaden to other mental health conditions
Further increase to international centres. Revised protocols and apply for specials medicine registration.
4) Global Growth
Continue to grow the global market access team. Potential to identify signals for a joint RCT study.
Psychedelic based psychotherapy
Modern science is now thriving to understand the neuro-chemical interactions and medicinal benefits of these substances in controlled, quantifiable clinical settings. With established research continuing to show safe physiological and psychological responses to these compounds. Now is the time to explore the extraordinary therapeutic potential on larger patient cohorts and in the real-world setting.
Clinical Trials
Vs.
Real World Evidence
FDA Breakthrough designation
In October, the Food and Drug Administration took the extraordinary step of granting psilocybin therapy for depression a “breakthrough therapy” designation. That means the treatment has demonstrated such potential that the FDA has decided to expedite its development and review process. It’s a sign of how far the research and the public perception of psychedelics have come.
Psilocybin based medicines
These are natural plants that can help you with cancer-related, depression, anxiety, thanatophobia. Psilocybin is a naturally occurring psychedelic compound found in over 180 species of mushrooms. The effect of psilocybin is due to its effects on serotonin receptors in the brain. The active compound with in psilocybin Tryptamine chemically related to the amino acid tryptophan, and is structurally similar to the neurotransmitter serotonin.
Proven safety
Psilocybin also has strong safety data based on studies conducted before prohibition, and so the FDA has allowed a small number of small clinical trials to move forward.
Continued clinical sucess
From the 2000’s psilocybin research has begun
– November 30, 2016
Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby and Brian L Schmidt.
– November 30, 2016
Roland R Griffiths, Matthew W Johnson1, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano and Margaret A Klinedinst.
– September 6, 2010
Charles S Grob, Alicia L Danforth, Gurpreet S Chopra, Marycie Hagerty, Charles R McKay, Adam L Halberstadt, George R Greer.
Let us tell you more.
We will email you to start the conversation.